Cynata Therapeutics Says Final Participant in Phase Two Acute Graft Versus Host Disease Drug Candidate Trial Completes Evaluation Period
MT Newswires Live
Mar 30
Cynata Therapeutics (ASX:CYP) said the 100-day primary evaluation period was completed for the final participant enrolled in its phase two clinical trial of its CYP-001 drug candidate in adults with acute graft versus host disease, according to a Monday Australian bourse filing.
A total of 65 participants were enrolled in the trial, and the participants were randomized to receive either steroids plus CYP-001 or steroids plus placebo.
The primary endpoint is the overall response rate at day 28, and results are anticipated in June.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.